Sandbox g12: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
* Risk categories for antimicrobial agents known to have an association with TdP<ref>{{Cite web | title = Arizona Center for Education and Research on Therapeutics | url = http://www.torsades.org }}</ref> | |||
* Risk categories for antimicrobial agents known to have an association with TdP<ref>{{ | |||
:* '''Drugs with known TdP risk''' | :* '''Drugs with known TdP risk''' | ||
::* [[Azithromycin|Azithromycin (Zithromax®, Zmax®)]] | ::* [[Azithromycin|Azithromycin (Zithromax®, Zmax®)]] | ||
| Line 32: | Line 31: | ||
::* [[Trimethoprim-Sulfamethoxazole|Trimethoprim-Sulfamethoxazole (Septra®, Bactrim®, Sulfatrim®, Biseptol®, Co-trimoxazole®, Cotrim®, Septrin®, Trisul®)]] | ::* [[Trimethoprim-Sulfamethoxazole|Trimethoprim-Sulfamethoxazole (Septra®, Bactrim®, Sulfatrim®, Biseptol®, Co-trimoxazole®, Cotrim®, Septrin®, Trisul®)]] | ||
* Torsades de pointes risk stratification schedules for antimicrobial agents | * Torsades de pointes risk stratification schedules for antimicrobial agents<ref>{{Cite journal| issn = 0012-6667| volume = 64| issue = 10| pages = 1091–1124| last = Owens| first = Robert C.| title = QT prolongation with antimicrobial agents: understanding the significance| journal = Drugs| date = 2004| pmid = 15139788}}</ref> | ||
:* '''Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)''' | :* '''Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)''' | ||
::* Not available | ::* Not available | ||
Revision as of 21:33, 31 May 2015
- Risk categories for antimicrobial agents known to have an association with TdP[1]
- Drugs with known TdP risk
- Azithromycin (Zithromax®, Zmax®)
- Chloroquine (Aralen®)
- Ciprofloxacin (Cipro®, Cipro-XR®, Neofloxin®)
- Clarithromycin (Biaxin®, Prevpac®)
- Erythromycin (A/T/S®, Akne-Mycin®, Emgel®, Ery-Tab®, Eryc®, Erycette®, Eryderm®, Erygel®)
- Halofantrine (Halfan®)
- Levofloxacin (Levaquin®, Tavanic®)
- Moxifloxacin (Avelox®, Avalox®, Avelon®)
- Pentamidine (Pentam®)
- Sparfloxacin (Zagam®)
- Drugs with possible TdP risk
- Bedaquiline (Sirturo®)
- Dihydroartemisinin-Piperaquine (Eurartesim®)
- Gatifloxacin (Tequin®)
- Gemifloxacin (Factive®)
- Norfloxacin (Noroxin®, Ambigram®)
- Ofloxacin (Floxin®)
- Roxithromycin (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)
- Telavancin (Vibativ®)
- Telithromycin (Ketek®)
- Drugs with conditional TdP risk
- Drugs to be avoided by congenital Long QT
- Torsades de pointes risk stratification schedules for antimicrobial agents[2]
- Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)
- Not available
- Schedule II (Significant risk for TdP, particularly when coadministered with CYP inhibitors, relatively potent IKr blockade)
- Not available
- Schedule III (Risk for TdP is described, IKr blockade, particularly when coadministered with CYP inhibitors)
- Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)
- Schedule V (Questionable/minimal risk for QT interval prolongation/TdP)